跳至主要内容
临床试验/DRKS00007966
DRKS00007966招募中不适用

DZNE – Longitudinal Cognitive Impairment and Dementia Study - DELCODE

Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)0 个研究点目标入组 1,000 人开始时间: 2015年5月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
60 Years 至 90 Years(—)
性别
All

入选标准

  • General inclusion criteria:
  • informed consent, incl. informed consent for lumbar puncture
  • presence of an informant, who is willing to provide information on the participant throughout the study
  • presence of an informant, who is not participating in the study and willing to provide information on the healthy control throughout the study
  • fluent German language abilities
  • age >/= 60 years
  • Inclusion criteria for respective groups of interest:
  • SCD Subjects:
  • score in the normal range (1.5 SD) of any of the CERAD+ tests at initial clinical assessment prior to study participation in the memory clinic
  • patient’s report of cognitive (e.g. memory) decline, about which (s)he expresses concerns (time of onset between the last 6 months and 5 years)
  • Siblings of patients with AD dementia:
  • presence of first degree sibling/ siblings with AD dementia, diagnosed in an expert setting (memory clinic)
  • score in the normal range of cognitive assessments at the baseline visit according to 2.2.2.4.
  • MCI Subjects:
  • perform 1.5 SD below the normal range in the delayed recall trial of the CERAD-wordlist at initial clinical assessment prior to study participation in the memory clinic
  • subjective cognitive decline by the patient can be present or not
  • either the subject or an informant or a clinician has to report a decline in cognitive function causing concerns.
  • the subjects must not fulfill dementia criteria.
  • AD Subjects:
  • must fulfill the clinical NINDCS/ADRDA criteria of probable AD (McKhann et al., 2011)
  • Healthy Controls or 3. Person, who provides information on the particitpantl throughout the study:
  • must negate subjective cognitive decline with concerns
  • must perform in the normal range of cognitive assessments at the baseline visit according to 2.2.2.4.
  • must not have a known first degree relative with dementia (parents > 75y of age or older without dementia)

排除标准

  • lack of capability to give informed consent
  • any condition that clearly interferes with participation in the study
  • any condition that interferes with the clinical or neuropsychological study procedures
  • sensory impairment that prevents or significantly interferes with neuropsychological testing
  • contraindication for both MRI and lumbar puncture
  • severe or unstable medical condition
  • current major depressive episode
  • psychotic disorder, bipolar disorder, substance abuse at present or in the past
  • neurodegenerative disorder other than AD
  • vascular dementia
  • history of stroke with residual symptoms
  • clinical significant abnormalities in Vit. B12 or TSH (not applicable for controls and relatives)
  • current or past unstable malignant disease with a reduced life expectancy (< 2 years)
  • chronic use of psychoactive drugs with sedative or anticholinergic effects
  • use of antidementia drugs in SCD, healthy siblings, MCI (Ginkgo is permitted) and in control subjects
  • investigational agents for treatment of dementia or cognitive impairment 4 weeks prior to study entry. Participation in a study using investigational medicinal products will lead to exclusion.

研究者

发起方
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)

相似试验